Thiazolidinedione Therapy for Managing Metabolic Syndrome

MOspace/Manakin Repository

Breadcrumbs Navigation

Thiazolidinedione Therapy for Managing Metabolic Syndrome

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/11924

[+] show full item record


Title: Thiazolidinedione Therapy for Managing Metabolic Syndrome
Author: Geurin, Michael D.; St. Anna, Leilani
Keywords: cardiac events
preventative measures
Date: 2010-12-15
Publisher: Family Physicians Inquiries Network
Citation: American Family Physician, 82(128) 2010: [1553]-1554.
Abstract: There is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting. (Strength of Recommendation: B, based on a single randomized controlled trial). Effects of TZD therapy on nonglycemic markers of metabolic syndrome are inconsistent compared with the effects of other hypoglycemic medications.
URI: http://hdl.handle.net/10355/11924

This item appears in the following Collection(s)

[+] show full item record